Zavoico, senior life sciences analyst at investment research firm MLV, forecasts that the bioscan removal will enable Spectrum to post record earnings in the fiscal third quarter of 2012.
FORBES: Spectrum Pharmaceuticals Gets Lift from FDA Action On One Of Its Cancer Treatments